MovDisordV3, PascalFrancis, Curation, bibRecord, 000B92

Long-term outcome of clozapine use for psychosis in Parkinsonian patients

Identifieur interne : 000B92 ( PascalFrancis/Curation ); précédent : 000B91; suivant : 000B93

Long-term outcome of clozapine use for psychosis in Parkinsonian patients

Auteurs : Hubert H. Fernandez [États-Unis] ; Edward M. Donnelly [États-Unis] ; Joseph H. Friedman [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2004.

RBID : Pascal:04-0454060

Descripteurs français

Pascal (Inist)
- Psychose, Pronostic, Clozapine, Système nerveux pathologie, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Clozapine, Human, Nervous system diseases, Prognosis, Psychosis.

Abstract

A retrospective analysis was carried out on 39 parkinsonian patients on clozapine treatment ≥24 months for psychosis. The cohort had a mean age of 76 years and an average clozapine dose of 47 mg/day over 60 months of clozapine use. Of 39 patients, 13 (33%) patients were eventually admitted to nursing homes. 6 (46%) of whom died over a period of 5 years. The overall 5-year mortality rate in this cohort was 44% (17/39). Of 39 patients, 33 (85%) had continued partial/good response and 5 (13%) had complete resolution of psychosis. None discontinued clozapine due to motor worsening. Among patients who responded early on, the long-term efficacy of clozapine for psychosis was sustained. The risk of nursing home placement and mortality among parkinsonian patients treated with clozapine for psychosis in this geriatric cohort was better than that reported previously. Our data are more consistent with recently published long-term outcome data suggesting an improvement in the prognosis of parkinsonian patients with psychosis with the use of atypical antipsychotic agents such as clozapine.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 19`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Long-term outcome of clozapine use for psychosis in Parkinsonian patients`
A11	`01`	`1`		`@1 FERNANDEZ (Hubert H.)`
A11	`02`	`1`		`@1 DONNELLY (Edward M.)`
A11	`03`	`1`		`@1 FRIEDMAN (Joseph H.)`
A14	`01`			`@1 Department of Clinical Neurosciences, Brown University School of Medicine @2 Providence, Rhode Island @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A20				`@1 831-833`
A21				`@1 2004`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000113929420150`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 9 ref.`
A47	`01`	`1`		`@0 04-0454060`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 A retrospective analysis was carried out on 39 parkinsonian patients on clozapine treatment ≥24 months for psychosis. The cohort had a mean age of 76 years and an average clozapine dose of 47 mg/day over 60 months of clozapine use. Of 39 patients, 13 (33%) patients were eventually admitted to nursing homes. 6 (46%) of whom died over a period of 5 years. The overall 5-year mortality rate in this cohort was 44% (17/39). Of 39 patients, 33 (85%) had continued partial/good response and 5 (13%) had complete resolution of psychosis. None discontinued clozapine due to motor worsening. Among patients who responded early on, the long-term efficacy of clozapine for psychosis was sustained. The risk of nursing home placement and mortality among parkinsonian patients treated with clozapine for psychosis in this geriatric cohort was better than that reported previously. Our data are more consistent with recently published long-term outcome data suggesting an improvement in the prognosis of parkinsonian patients with psychosis with the use of atypical antipsychotic agents such as clozapine.
C02	`01`	`X`		`@0 002B17`
C03	`01`	`X`	`FRE`	`@0 Psychose @5 01`
C03	`01`	`X`	`ENG`	`@0 Psychosis @5 01`
C03	`01`	`X`	`SPA`	`@0 Psicosis @5 01`
C03	`02`	`X`	`FRE`	`@0 Pronostic @5 02`
C03	`02`	`X`	`ENG`	`@0 Prognosis @5 02`
C03	`02`	`X`	`SPA`	`@0 Pronóstico @5 02`
C03	`03`	`X`	`FRE`	`@0 Clozapine @2 NK @2 FR @5 03`
C03	`03`	`X`	`ENG`	`@0 Clozapine @2 NK @2 FR @5 03`
C03	`03`	`X`	`SPA`	`@0 Clozapina @2 NK @2 FR @5 03`
C03	`04`	`X`	`FRE`	`@0 Système nerveux pathologie @5 04`
C03	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 04`
C03	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 04`
C03	`05`	`X`	`FRE`	`@0 Homme @5 05`
C03	`05`	`X`	`ENG`	`@0 Human @5 05`
C03	`05`	`X`	`SPA`	`@0 Hombre @5 05`
N21				`@1 257`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002129

Links to Exploration step

Pascal:04-0454060

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Long-term outcome of clozapine use for psychosis in Parkinsonian patients</title>
<author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Donnelly, Edward M" sort="Donnelly, Edward M" uniqKey="Donnelly E" first="Edward M." last="Donnelly">Edward M. Donnelly</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0454060</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0454060 INIST</idno>
<idno type="RBID">Pascal:04-0454060</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002129</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000B92</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Long-term outcome of clozapine use for psychosis in Parkinsonian patients</title>
<author><name sortKey="Fernandez, Hubert H" sort="Fernandez, Hubert H" uniqKey="Fernandez H" first="Hubert H." last="Fernandez">Hubert H. Fernandez</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Donnelly, Edward M" sort="Donnelly, Edward M" uniqKey="Donnelly E" first="Edward M." last="Donnelly">Edward M. Donnelly</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clozapine</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Prognosis</term>
<term>Psychosis</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Psychose</term>
<term>Pronostic</term>
<term>Clozapine</term>
<term>Système nerveux pathologie</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A retrospective analysis was carried out on 39 parkinsonian patients on clozapine treatment ≥24 months for psychosis. The cohort had a mean age of 76 years and an average clozapine dose of 47 mg/day over 60 months of clozapine use. Of 39 patients, 13 (33%) patients were eventually admitted to nursing homes. 6 (46%) of whom died over a period of 5 years. The overall 5-year mortality rate in this cohort was 44% (17/39). Of 39 patients, 33 (85%) had continued partial/good response and 5 (13%) had complete resolution of psychosis. None discontinued clozapine due to motor worsening. Among patients who responded early on, the long-term efficacy of clozapine for psychosis was sustained. The risk of nursing home placement and mortality among parkinsonian patients treated with clozapine for psychosis in this geriatric cohort was better than that reported previously. Our data are more consistent with recently published long-term outcome data suggesting an improvement in the prognosis of parkinsonian patients with psychosis with the use of atypical antipsychotic agents such as clozapine.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>19</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Long-term outcome of clozapine use for psychosis in Parkinsonian patients</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>FERNANDEZ (Hubert H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DONNELLY (Edward M.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>FRIEDMAN (Joseph H.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Clinical Neurosciences, Brown University School of Medicine</s1>
<s2>Providence, Rhode Island</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>831-833</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000113929420150</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>9 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0454060</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A retrospective analysis was carried out on 39 parkinsonian patients on clozapine treatment ≥24 months for psychosis. The cohort had a mean age of 76 years and an average clozapine dose of 47 mg/day over 60 months of clozapine use. Of 39 patients, 13 (33%) patients were eventually admitted to nursing homes. 6 (46%) of whom died over a period of 5 years. The overall 5-year mortality rate in this cohort was 44% (17/39). Of 39 patients, 33 (85%) had continued partial/good response and 5 (13%) had complete resolution of psychosis. None discontinued clozapine due to motor worsening. Among patients who responded early on, the long-term efficacy of clozapine for psychosis was sustained. The risk of nursing home placement and mortality among parkinsonian patients treated with clozapine for psychosis in this geriatric cohort was better than that reported previously. Our data are more consistent with recently published long-term outcome data suggesting an improvement in the prognosis of parkinsonian patients with psychosis with the use of atypical antipsychotic agents such as clozapine.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Psychose</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Psychosis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Psicosis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Clozapine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Clozapine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Clozapina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Human</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0>
<s5>05</s5>
</fC03>
<fN21><s1>257</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B92 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000B92 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:04-0454060
   |texte=   Long-term outcome of clozapine use for psychosis in Parkinsonian patients
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Long-term outcome of clozapine use for psychosis in Parkinsonian patients

Long-term outcome of clozapine use for psychosis in Parkinsonian patients

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri